Related Experiment Video
Updated: Aug 10, 2026
09:16
Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells
Published on: April 20, 2017
Glucagon-like Peptide 2
1Banting and Best Diabetes Center, The Toronto Hospital, University of Toronto, Toronto, Ontario, Canada M5G 2C4.
Trends in Endocrinology and Metabolism: TEM
|May 14, 1999
Summary
Glucagon-like peptide 2 (GLP-2) supports intestinal health by promoting cell growth and reducing cell death. This peptide enhances nutrient absorption and shows promise for treating gut inflammation and short bowel syndrome.
Area of Science:
- Gastroenterology
- Endocrinology
- Cell Biology
Background:
- Glucagon-like peptide 2 (GLP-2) is an incretin hormone secreted by enteroendocrine cells in response to nutrient intake.
- GLP-2 plays a crucial role in maintaining intestinal mucosal integrity and function.
- Its trophic effects on the gut epithelium are well-established.
Purpose of the Study:
- To elucidate the mechanisms by which GLP-2 influences intestinal epithelial cells.
- To explore the therapeutic potential of GLP-2 in gastrointestinal disorders.
- To investigate GLP-2's role in nutrient absorption and mucosal barrier function.
Main Methods:
- Studies involved analyzing GLP-2 secretion patterns.
- Investigated GLP-2's impact on crypt cell proliferation and apoptosis.
- Assessed GLP-2 effects on intestinal glucose transport and mucosal permeability in experimental models.
Main Results:
- GLP-2 administration stimulated intestinal crypt cell proliferation and inhibited cell death.
- GLP-2 was shown to enhance intestinal glucose transport.
- Decreased mucosal permeability and therapeutic benefits were observed in models of short bowel syndrome and gut inflammation.
Conclusions:
- GLP-2 is a key regulator of intestinal mucosal homeostasis.
- GLP-2 demonstrates significant therapeutic potential for inflammatory bowel diseases and short bowel syndrome.
- Further research into GLP-2's mechanisms could lead to novel gastrointestinal treatments.
More Related Videos
Related Concept Videos
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...